These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 23697926)

  • 41. Evaluation of (89)Zr-labeled human anti-CD147 monoclonal antibody as a positron emission tomography probe in a mouse model of pancreatic cancer.
    Sugyo A; Tsuji AB; Sudo H; Nagatsu K; Koizumi M; Ukai Y; Kurosawa G; Zhang MR; Kurosawa Y; Saga T
    PLoS One; 2013; 8(4):e61230. PubMed ID: 23577210
    [TBL] [Abstract][Full Text] [Related]  

  • 42.
    Fung K; Vivier D; Keinänen O; Sarbisheh EK; Price EW; Zeglis BM
    Molecules; 2020 May; 25(10):. PubMed ID: 32429033
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preclinical ImmunoPET Imaging Using a Zr-89-Labeled Anti-CD146 Monoclonal Antibody for Diagnosis of Melanoma.
    Guo X; Hu M; Zhang Q; Liu J; Shi J; Tang Y; Liu S; Guo J; Kong Y; Zhu H; Yang Z
    Mol Pharm; 2024 Sep; 21(9):4490-4497. PubMed ID: 39077827
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect of antibody protein dose of anti-renal cell carcinoma monoclonal antibodies in nude mice with renal cell carcinoma xenografts.
    Kranenborg MH; Boerman OC; de Weijert MC; Oosterwijk-Wakka JC; Corstens FH; Oosterwijk E
    Cancer; 1997 Dec; 80(12 Suppl):2390-7. PubMed ID: 9406688
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Molecular imaging of T cell co-regulator factor B7-H3 with
    Burvenich IJG; Parakh S; Lee FT; Guo N; Liu Z; Gan HK; Rigopoulos A; O'Keefe GJ; Gong SJ; Goh YW; Tochon-Danguy H; Scott FE; Kotsuma M; Hirotani K; Senaldi G; Scott AM
    Theranostics; 2018; 8(15):4199-4209. PubMed ID: 30128047
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials.
    Zhou GX; Ireland J; Rayman P; Finke J; Zhou M
    Urology; 2010 Feb; 75(2):257-61. PubMed ID: 19963243
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CD146-targeted immunoPET and NIRF Imaging of Hepatocellular Carcinoma with a Dual-Labeled Monoclonal Antibody.
    Hernandez R; Sun H; England CG; Valdovinos HF; Ehlerding EB; Barnhart TE; Yang Y; Cai W
    Theranostics; 2016; 6(11):1918-33. PubMed ID: 27570560
    [TBL] [Abstract][Full Text] [Related]  

  • 48. ImmunoPET of Malignant and Normal B Cells with
    Zettlitz KA; Tavaré R; Knowles SM; Steward KK; Timmerman JM; Wu AM
    Clin Cancer Res; 2017 Dec; 23(23):7242-7252. PubMed ID: 28928164
    [No Abstract]   [Full Text] [Related]  

  • 49. PET/CT with (124)I-cG250: great potential and some open questions.
    Khandani AH; Rathmell WK; Wallen EM; Ivanovic M
    AJR Am J Roentgenol; 2014 Aug; 203(2):261-2. PubMed ID: 25055257
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of Anti-LGR5 Antibodies by ImmunoPET for Imaging Colorectal Tumors and Development of Antibody-Drug Conjugates.
    Azhdarinia A; Voss J; Ghosh SC; Simien JA; Hernandez Vargas S; Cui J; Yu WA; Liu Q; Carmon KS
    Mol Pharm; 2018 Jun; 15(6):2448-2454. PubMed ID: 29718672
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Towards effective CAIX-targeted radionuclide and checkpoint inhibition combination therapy for advanced clear cell renal cell carcinoma.
    Kleinendorst SC; Oosterwijk E; Molkenboer-Kuenen J; Frielink C; Franssen GM; Boreel DF; Tamborino G; Gloudemans M; Hendrikx M; Kroon D; Hillen J; Bussink J; Muselaers S; Mulders P; Konijnenberg MW; Wheatcroft MP; Twumasi-Boateng K; Heskamp S
    Theranostics; 2024; 14(9):3693-3707. PubMed ID: 38948062
    [No Abstract]   [Full Text] [Related]  

  • 52. In vivo and in vitro characterizations of three 99mTc-labeled monoclonal antibody G250 preparations.
    Steffens MG; Oosterwijk E; Kranenborg MH; Manders JM; Debruyne FM; Corstens FH; Boerman OC
    J Nucl Med; 1999 May; 40(5):829-36. PubMed ID: 10319758
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Visualizing Galectin-3 Binding Protein Expression with ImmunoPET.
    Keinänen O; Sarrett SM; Delaney S; Rodriguez C; Dayts EJ; Capone E; Sauniere F; Ippoliti R; Sala G; Iacobelli S; Zeglis BM
    Mol Pharm; 2023 Jun; 20(6):3241-3248. PubMed ID: 37191353
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg.
    Bauer S; Oosterwijk-Wakka JC; Adrian N; Oosterwijk E; Fischer E; Wüest T; Stenner F; Perani A; Cohen L; Knuth A; Divgi C; Jäger D; Scott AM; Ritter G; Old LJ; Renner C
    Int J Cancer; 2009 Jul; 125(1):115-23. PubMed ID: 19384924
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma.
    Sham JG; Kievit FM; Grierson JR; Miyaoka RS; Yeh MM; Zhang M; Yeung RS; Minoshima S; Park JO
    J Nucl Med; 2014 May; 55(5):799-804. PubMed ID: 24627434
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Imaging of prostate cancer with immuno-PET and immuno-SPECT using a radiolabeled anti-EGP-1 monoclonal antibody.
    van Rij CM; Sharkey RM; Goldenberg DM; Frielink C; Molkenboer JD; Franssen GM; van Weerden WM; Oyen WJ; Boerman OC
    J Nucl Med; 2011 Oct; 52(10):1601-7. PubMed ID: 21865288
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts.
    Lee FT; Rigopoulos A; Hall C; Clarke K; Cody SH; Smyth FE; Liu Z; Brechbiel MW; Hanai N; Nice EC; Catimel B; Burgess AW; Welt S; Ritter G; Old LJ; Scott AM
    Cancer Res; 2001 Jun; 61(11):4474-82. PubMed ID: 11389078
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Trimeric Radiofluorinated Sulfonamide Derivatives to Achieve In Vivo Selectivity for Carbonic Anhydrase IX-Targeted PET Imaging.
    Lau J; Liu Z; Lin KS; Pan J; Zhang Z; Vullo D; Supuran CT; Perrin DM; Bénard F
    J Nucl Med; 2015 Sep; 56(9):1434-40. PubMed ID: 26205302
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing
    Cho H; Al-Saden N; Lam H; Möbus J; Reilly RM; Winnik MA
    Nucl Med Biol; 2020; 84-85():11-19. PubMed ID: 31931305
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.
    Rylova SN; Del Pozzo L; Klingeberg C; Tönnesmann R; Illert AL; Meyer PT; Maecke HR; Holland JP
    J Nucl Med; 2016 Jan; 57(1):96-102. PubMed ID: 26514172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.